claim: giuliani-free covid-19 therapy from celularity nabs fda speedy trial start
evidence_1: trials need to be expedited. it seems he got his wish: today, new jersey-based celularity said it has been given the all-clear from the fda to start its clinical trial of cynk-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with covid-19.